Project factsheets

Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).

IHI/IMI2/IMI1

Status

Call

Programmes

Disease areas

Products

Tools and resources to improve drug development

ALL # A B C D E F G H I K L M N O P Q R S T U V W Z

Clear all filters

Displaying 16 projects and 0 programmes

END2AMR

European novel drug research to address microbial infections and drug resistance

LIGAND-AI

Protein-ligand data generation at scale to support computational hit finding and optimization

Ongoing IHI Target identification Drug discovery

ADAPTED

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

Closed IMI2 Neurodegenerative diseases Alzheimer's disease Stem cells Target identification Drug discovery

CARE

Corona accelerated R&D in Europe

Ongoing IMI2 Respiratory diseases Infectious diseases Coronaviruses Conducting clinical trials Target identification Drug discovery

ESCulab

European screening centre; unique library for attractive biology

Closed IMI2 Target identification Drug discovery

EUbOPEN

EUbOPEN: Enabling and unlocking biology in the OPEN

Ongoing IMI2 Target identification Drug discovery

IMPRiND

Inhibiting misfolded protein propagation in neurodegenerative diseases

Closed IMI2 Neurodegenerative diseases Alzheimer's disease Stem cells Target identification Drug discovery

MAD-CoV 2

Modern approaches for developing antivirals against SARS-CoV 2

Ongoing IMI2 Respiratory diseases Infectious diseases Coronaviruses Target identification

PD-MitoQUANT

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

Closed IMI2 Neurodegenerative diseases Tools for predicting/monitoring efficacy Disease taxonomy Target identification Drug discovery

PHAGO

Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33

Closed IMI2 Neurodegenerative diseases Alzheimer's disease Stem cells Target identification Drug discovery

PRISM

Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Closed IMI2 Neurodegenerative diseases Psychiatric diseases Alzheimer's disease Clinical trial design Disease taxonomy Target identification Drug discovery

PRISM 2

Psychiatric ratings using intermediate stratified markers 2

Closed IMI2 Neurodegenerative diseases Psychiatric diseases Alzheimer's disease Disease taxonomy Target identification

REsolution

Add medical genetic solutions to RESOLUTE (REsolution)

Closed IMI2 Tools for predicting/monitoring efficacy Disease taxonomy Target identification

ReSOLUTE

Research empowerment on solute carriers

Closed IMI2 Tools for predicting/monitoring efficacy Disease taxonomy Target identification

RespiriNTM

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials Target identification

APPROACH

Applied public-private research enabling osteoarthritis clinical headway

Closed IMI1 Osteoarthritis Target identification